OHSU
Return to Listing

3 result(s) for MEK162

PI Name Protocol # Title
Matthew Taylor IRB00009443 A Randomized Phase III, Open Label, Multicenter, Two-Arm Study Comparing the Efficacy of MEK162 versus Decarbazine in Patients with Advanced Unresectable or Metastatic NRAS Mutation-Positive Melanoma
Matthew Taylor IRB00010426 Modular Phase 2 Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors
Matthew Taylor IRB00010630 CLGX818X2109: The LOGIC 2 trial, A phase II, multi-center, open-label study of sequential LGX818/MEK162 combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally advanced or metastatic BRAF V600 melanoma.
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program